CD4 Lymphocyte Count

• 

  Subject Areas on Research

  • 9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity. 
  • A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIV(mac)251 challenge in rhesus Macaques. 
  • A North American multilaboratory study of CD4 counts using flow cytometric panLeukogating (PLG): a NIAID-DAIDS Immunology Quality Assessment Program Study. 
  • A comparison of HIV-positive patients with and without infective endocarditis: an echocardiographic study--the Emory Endocarditis Group experience. 
  • A comparison of height and weight velocity as a part of the composite endpoint in pediatric HIV. 
  • A comparison of performance-based measures of function in HIV-associated neurocognitive disorders. 
  • A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team. 
  • A phase I/II study of the protease inhibitor indinavir in children with HIV infection. 
  • A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. 
  • A placebo-controlled trial of ranitidine in patients with early human immunodeficiency virus infection. 
  • A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team. 
  • A randomized controlled trial of health information exchange between human immunodeficiency virus institutions. 
  • A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. 
  • A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team. 
  • A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy. 
  • Acute HIV-1 infection in the Southeastern United States: a cohort study. 
  • Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons. 
  • Amino acid residue at position 13 in HLA-DR beta chain plays a critical role in the development of Kaposi's sarcoma in AIDS patients. 
  • An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. 
  • An information criterion for marginal structural models. 
  • An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. 
  • Analysis of the immune responses in chimpanzees infected with HIV type 1 isolates. 
  • Antiretroviral monotherapy in early stage human immunodeficiency virus disease has no detectable effect on virus load in peripheral blood and lymph nodes. 
  • Antiretroviral rounds. A communication conundrum. 
  • Antiretroviral therapy effects on genetic and morphologic end points in lymphocytes and sperm of men with human immunodeficiency virus infection. 
  • Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV. 
  • Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. 
  • Application of lipoarabinomannan antigen in tuberculosis diagnostics: current evidence. 
  • Appropriate use of nevirapine for long-term therapy. 
  • Association of aflatoxin B1 levels with mean CD4 cell count and uptake of ART among HIV infected patients: A prospective study. 
  • Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization. 
  • B cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 T cell count, viral load and humoral immune responses. 
  • Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. 
  • Bipolar disorder is associated with HIV transmission risk behavior among patients in treatment for HIV. 
  • Birth Weight and Preterm Delivery Outcomes of Perinatally vs Nonperinatally Human Immunodeficiency Virus-Infected Pregnant Women in the United States: Results From the PHACS SMARTT Study and IMPAACT P1025 Protocol. 
  • Breadth and magnitude of antigen-specific antibody responses in the control of plasma viremia in simian immunodeficiency virus infected macaques. 
  • Brief Report: Relationship Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease in Persons With HIV. 
  • Broadly Neutralizing Antibody Responses in a Subset of HIV-1-Infected Individuals in Chennai, India. 
  • CD4 enumeration technologies: a systematic review of test performance for determining eligibility for antiretroviral therapy. 
  • CD4 immunophenotyping in HIV infection. 
  • CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials. 
  • CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States. 
  • CD83 expression influences CD4+ T cell development in the thymus. 
  • Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. 
  • Cervical dysplasia in women infected with the human immunodeficiency virus (HIV): a correlation with HIV viral load and CD4+ count. 
  • Cervical intraepithelial neoplasia in HIV-infected women in a southeastern US population. 
  • Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. 
  • Changes in HIV Outcomes Following Depression Care in a Resource-Limited Setting: Results from a Pilot Study in Bamenda, Cameroon. 
  • Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. 
  • Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. 
  • Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals. 
  • Chronic kidney disease in HIV infection: an urban epidemic. 
  • Chronic multifocal retinal infiltrates in patients infected with human immunodeficiency virus. 
  • Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children. 
  • Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers. 
  • Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with Walter Reed stage 2 human immunodeficiency virus infection: results of ACTG protocol 042. 
  • Cocaine dependence does not contribute substantially to white matter abnormalities in HIV infection. 
  • Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994-1997: incidence, risk factors, and prevention. 
  • Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. 
  • Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team. 
  • Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. 
  • Comparative effectiveness of dual vs. single-action antidepressants on HIV clinical outcomes in HIV-infected people with depression. 
  • Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview. 
  • Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. 
  • Compensatory activation in fronto-parietal cortices among HIV-infected persons during a monetary decision-making task. 
  • Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy. 
  • Contributions to early HIV diagnosis among patients linked to care vary by testing venue. 
  • Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. 
  • Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. 
  • Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. 
  • Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group. 
  • Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. 
  • Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease. 
  • Cytomegalovirus retinitis in HIV-infected patients with elevated CD4+ counts. 
  • DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus. 
  • DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory. 
  • Decreased interferon-alpha production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors. 
  • Decreased sexual risk behavior in the era of HAART among HIV-infected urban and rural South Africans attending primary care clinics. 
  • Decreasing CD4+ T-cell count during suppressed or low-level viraemia in patients with HIV infection. 
  • Deficient antibody-dependent cellular cytotoxicity against human immunodeficiency virus (HIV)-expressing target cells in perinatal HIV infection. 
  • Defining the rural HIV epidemic: correlations of 3 definitions--South Carolina, 2005-2011. 
  • Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. 
  • Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. 
  • Depression and Engagement in Care Among Newly Diagnosed HIV-Infected Adults in Johannesburg, South Africa. 
  • Detection of Epstein-Barr virus in transformations of low-grade B-cell lymphomas after fludarabine treatment. 
  • Determinants of disease in the simian immunodeficiency virus-infected rhesus macaque: characterizing animals with low antibody responses and rapid progression. 
  • Diagnosing HIV infection in primary care settings: missed opportunities. 
  • Disparities in viral load and CD4 count trends among HIV-infected adults in South Carolina. 
  • Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy. 
  • Drug resistance and HCV coinfection in former blood donors infected with HIV type 1 in China. 
  • Drug susceptibility and resistance mutations after first-line failure in resource limited settings. 
  • Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164. 
  • Early intensification with abacavir in subjects at high risk for incomplete viral suppression. 
  • Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania. 
  • Economic evaluation of ART in resource-limited countries. 
  • Editorial comment: renal insufficiency in HIV-infected patients may not always be HIVAN. 
  • Effect of UV-B phototherapy on plasma HIV type 1 RNA viral level: a self-controlled prospective study. 
  • Effect of directly observed antiretroviral therapy compared to self-administered antiretroviral therapy on adherence and virological outcomes among HIV-infected prisoners: a randomized controlled pilot study. 
  • Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection. 
  • Effect of pregnancy and human immunodeficiency virus infection on intracellular interleukin-2 production patterns. 
  • Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee. 
  • Effects of Antiretroviral Therapy and Depressive Symptoms on All-Cause Mortality Among HIV-Infected Women. 
  • Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection. 
  • Emmonsia helica Infection in HIV-Infected Man, California, USA. 
  • Establishment of reference range of CD4 T-lymphocyte in healthy Nepalese adults. 
  • Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. 
  • Estimating correlation by using a general linear mixed model: evaluation of the relationship between the concentration of HIV-1 RNA in blood and semen. 
  • Estimating the parameters in the Cox model when covariate variables are measured with error. 
  • Estimation and prediction with HIV-treatment interruption data. 
  • Evaluation of T-lymphocyte subsets present in semen and peripheral blood of healthy donors: a report from the heterosexual transmission study. 
  • Evaluation of a method for counting absolute numbers of cells with a flow cytometer. 
  • Evaluation of surrogate markers and clinical outcomes in two-year follow-up of eighty-six human immunodeficiency virus-infected pediatric patients. 
  • Evaluation of the blood stabilizers TransFix and Cyto-Chex BCT for low-cost CD4 T-cell methodologies. 
  • Factors associated with changes in the use of antiretroviral therapy by a cohort of homosexual men infected with human immunodeficiency virus type 1. 
  • Factors associated with failure to list HIV-positive kidney transplant candidates. 
  • Factors associated with recurrence of cervical intraepithelial neoplasia 2+ after treatment among HIV-infected women in Western Kenya. 
  • Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. 
  • Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. 
  • Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor. 
  • Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. 
  • Genetic influence of CCR5, CCR2, and SDF1 variants on human immunodeficiency virus 1 (HIV-1)-related disease progression and neurological impairment, in children with symptomatic HIV-1 infection. 
  • Graft survival in a rhesus renal transplant model after immunotoxin-mediated T-cell depletion is enhanced by mycophenolate and steroids. 
  • Growth as a prognostic indicator in children with human immunodeficiency virus infection treated with zidovudine. AIDS Clinical Trials Group Protocol 043 Study Group. 
  • Growth, survival and viral load in symptomatic childhood human immunodeficiency virus infection. 
  • HIV and older adults: clinical outcomes in the era of HAART. 
  • HIV community viral load trends in South Carolina. 
  • HIV serostatus disclosure in the treatment cascade: evidence from Northern Tanzania. 
  • HIV+ caregivers and HIV+ non-caregivers: differences in sociodemographics, immune functioning, and quality-of-life. 
  • HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group. 
  • HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. 
  • HIV-associated nephropathy is a late, not early, manifestation of HIV-1 infection. 
  • Healthcare retention and clinical outcomes among adolescents living with HIV after transition from pediatric to adult care: a systematic review. 
  • Herpes virus infections, HIV, and disease progression. Guarded optimism. 
  • Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. 
  • Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors. 
  • Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. 
  • High prevalence of cervical squamous intraepithelial lesions in women on antiretroviral therapy in Cameroon: Is targeted screening feasible? 
  • Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. 
  • Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. 
  • Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge. 
  • Human T cell reconstitution in DiGeorge syndrome and HIV-1 infection. 
  • Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group. 
  • Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. 
  • Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings. 
  • Hypertension Among HIV-infected Patients in Clinical Care, 1996-2013. 
  • Hyponatremia in pediatric patients with HIV-1 infection. 
  • IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. 
  • Immune failure in the absence of profound CD4+ T-lymphocyte depletion in simian immunodeficiency virus-infected rapid progressor macaques. 
  • Immune reconstitution in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy: a cohort study. 
  • Immune reconstitution inflammatory syndrome involving the central nervous system in a patient with HIV infection: a case report and review of literature. 
  • Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. 
  • Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. 
  • Immunization against SIVmne in macaques using multigenic DNA vaccines. 
  • Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women. 
  • Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy. 
  • Immunologic Aging in Adults with Congenital Heart Disease: Does Infant Sternotomy Matter? 
  • Immunologic profile of human immunodeficiency virus-infected patients during viral remission and relapse on antiretroviral therapy. 
  • Immunologic resolution of human chronic graft-versus-host disease. 
  • Improvement of HAART in Brazil, 1998-2008: a nationwide assessment of survival times after AIDS diagnosis among men who have sex with men. 
  • Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. 
  • Incidence of clinical AIDS conditions in a cohort of homosexual men with CD4+ cell counts < 100/mm3. Multicenter AIDS Cohort Study. 
  • Increased circulating interleukin-7 levels in HIV-1-infected women. 
  • Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy. 
  • Initiation of antiretroviral therapy in HIV-infected adults with skin complaints in northern Tanzania. 
  • Inter- and intrainstitutional evaluation of automated volumetric capillary cytometry for the quantitation of CD4- and CD8-positive T lymphocytes in the peripheral blood of persons infected with human immunodeficiency virus. Site Investigators and the NIAID New CD4 Technologies Focus Group. 
  • Interactions between highly active antiretroviral therapy and over-the-counter agents: a cautionary note. 
  • Interruption of antiretroviral therapy is associated with increased plasma cystatin C. 
  • Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. 
  • Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected children and infants in northern Tanzania. 
  • Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. 
  • Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. 
  • Lack of usefulness of radiographic screening for pulmonary disease in asymptomatic HIV-infected adults. Pulmonary Complications of HIV Infection Study Group. 
  • Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party. 
  • Levels of Foxp3 in regulatory T cells reflect their functional status in transplantation. 
  • Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS Treatment. 
  • Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge. 
  • Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine. 
  • Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance. 
  • Low Levels of Physical Activity Among Older Persons Living with HIV/AIDS Are Associated with Poor Physical Function. 
  • Low sensitivity of T-cell based detection of tuberculosis among HIV co-infected Tanzanian in-patients. 
  • Microalbuminuria predicts overt proteinuria among patients with HIV infection. 
  • Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. 
  • Mortality and loss to follow-up among HAART initiators in rural South Africa. 
  • Multilocular thymic cysts in children with human immunodeficiency virus infection: clinical and pathologic aspects. 
  • Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors. 
  • Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial. 
  • NLRC3 negatively regulates CD4+ T cells and impacts protective immunity during Mycobacterium tuberculosis infection. 
  • Naïve T cells are maintained in the periphery during the first 3 months of acute HIV-1 infection: implications for analysis of thymus function. 
  • Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. 
  • Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. 
  • Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. 
  • Non-AIDS-defining events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban setting. 
  • Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. 
  • Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate. 
  • Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. 
  • Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies. 
  • Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. 
  • Patient-Initiated Repackaging of Antiretroviral Therapy, Viral Suppression and Drug Resistance. 
  • Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. 
  • Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. 
  • Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. 
  • Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. 
  • Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia. 
  • Phase I/II trial of intermittent subcutaneous IL-2 administration in pediatric patients with moderate immune suppression: results of Pediatric AIDS Clinical Trials Study 402. 
  • Phenotypic Variability Correlates with Clinical Outcome in Cryptococcus Isolates Obtained from Botswanan HIV/AIDS Patients. 
  • Physical exercise is associated with less neurocognitive impairment among HIV-infected adults. 
  • Plasma and Intracellular Concentrations in HIV-Infected Patients Requiring Hemodialysis Dosed With Tenofovir Disoproxil Fumarate and Emtricitabine. 
  • Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers. 
  • Posterior segment manifestations of active ocular syphilis, their response to a neurosyphilis regimen of penicillin therapy, and the influence of human immunodeficiency virus status on response. 
  • Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. 
  • Predicting CD4 lymphocyte count <200 cells/mm(3) in an HIV type 1-infected African population. 
  • Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study. 
  • Predictors and outcomes of Mycobacterium tuberculosis bacteremia among patients with HIV and tuberculosis co-infection enrolled in the ACTG A5221 STRIDE study. 
  • Predictors of glycaemic control among HIV-positive veterans with diabetes. 
  • Predictors of non-adherence to antiretroviral therapy among HIV infected patients in northern Tanzania. 
  • Preoperative immune status determines anal condyloma recurrence after surgical excision. 
  • Prevalence and severity of cervical squamous intraepithelial lesion in a tertiary hospital in northern Tanzania. 
  • Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States. 
  • Primary care of HIV infection. 
  • Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy. 
  • Prognostic value of combined response markers among human immunodeficiency virus-infected persons: possible aid in the decision to change zidovudine monotherapy. 
  • Progression to AIDS: the effects of stress, depressive symptoms, and social support. 
  • Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control. 
  • Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal. 
  • Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies. 
  • Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles. 
  • Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. 
  • Pulmonary immune-compartment-specific interferon gamma responses in HIV-infected individuals with active tuberculosis (TB) in an area of high TB prevalence. 
  • Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS. 
  • Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. 
  • Reduced adherence to antiretroviral therapy among HIV-infected Tanzanians seeking cure from the Loliondo healer. 
  • Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. 
  • Relation of lifetime trauma and depressive symptoms to mortality in HIV. 
  • Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients. 
  • Relationship of self-reported prior testing history to undiagnosed HIV positivity and HIV risk. 
  • Resolution of intractable molluscum contagiosum in a human immunodeficiency virus-infected patient after institution of antiretroviral therapy with ritonavir. 
  • Restricted isotype, distinct variable gene usage, and high rate of gp120 specificity of HIV-1 envelope-specific B cells in colostrum compared with those in blood of HIV-1-infected, lactating African women. 
  • Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: the Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS (SOCA) Research Group in Collaboration with the AIDS Clinical Trials Group (ACTG). 
  • Rhesus macaques that become systemically infected with pathogenic SHIV 89.6-PD after intravenous, rectal, or vaginal inoculation and fail to make an antiviral antibody response rapidly develop AIDS. 
  • Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia. 
  • Risk factors influencing antibody responses to Kaposi's sarcoma-associated herpesvirus latent and lytic antigens in patients under antiretroviral therapy. 
  • Risk of Skin Cancers in Older Persons Living With HIV: A Systematic Review. 
  • Risk patterns preceding diagnosis among newly HIV-diagnosed men who have sex with men in New York City. 
  • Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. 
  • Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. 
  • Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. 
  • Semiparametric estimation of treatment effect in a pretest-posttest study. 
  • Serum leptin and CD4+ T lymphocytes in HIV+ children during highly active antiretroviral therapy. 
  • Sexually transmitted infections and immune activation among HIV-infected but virally suppressed youth on antiretroviral therapy. 
  • Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression. 
  • Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. 
  • Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. 
  • Signature for long-term vaccine-mediated control of a Simian and human immunodeficiency virus 89.6P challenge: stable low-breadth and low-frequency T-cell response capable of coproducing gamma interferon and interleukin-2. 
  • Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses. 
  • Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up. 
  • Status of selected nutrients and progression of human immunodeficiency virus type 1 infection. 
  • Structural connectome differences in HIV infection: brain network segregation associated with nadir CD4 cell count. 
  • Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. 
  • Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. 
  • Suboptimal HIV Testing Among Patients Admitted With Pneumonia: A Missed Opportunity. 
  • Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. 
  • Suppression of adaptive immune responses during primary SIV infection of sabaeus African green monkeys delays partial containment of viremia but does not induce disease. 
  • Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS Cohort Study Group. 
  • Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. 
  • Technologies for global health. 
  • Th1 inflammatory response with altered expression of profibrotic and vasoactive mediators in AT1A and AT1B double-knockout mice. 
  • The Immunology Quality Assessment Proficiency Testing Program for CD3⁺4⁺ and CD3⁺8⁺ lymphocyte subsets: a ten year review via longitudinal mixed effects modeling. 
  • The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. 
  • The impact of highly active antiretroviral therapy on activities of daily living in HIV-infected adults in South Africa. 
  • The natural history of HIV-1 infection in young Thai men after seroconversion. 
  • The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine. 
  • The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. 
  • The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. 
  • The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328. 
  • Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques. 
  • Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors. 
  • Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. 
  • Total lymphocyte count and World Health Organization pediatric clinical stage as markers to assess need to initiate antiretroviral therapy among human immunodeficiency virus-infected children in Moshi, Northern Tanzania. 
  • Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. 
  • Transitional probability-based model for HPV clearance in HIV-1-positive adolescent females. 
  • Treatment and CD4+ T cell count recovery among antiretroviral therapy-naive patients with HIV/AIDS. 
  • Treatment-mediated changes in human immunodeficiency virus (HIV) type 1 RNA and CD4 cell counts as predictors of weight growth failure, cognitive decline, and survival in HIV-infected children. 
  • Trends in Prevalence of Advanced HIV Disease at Antiretroviral Therapy Enrollment - 10 Countries, 2004-2015. 
  • Two-year clinical and immune outcomes in human immunodeficiency virus-infected children who reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy. 
  • Use of glomerular filtration rate estimating equations for drug dosing in HIV-positive patients. 
  • Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation. 
  • VERITAS?: A time for VERIQAS™ and a new approach to training, education, and the quality assessment of CD4+ T lymphocyte counting (I). 
  • Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660. 
  • Vaccine-elicited immune responses prevent clinical AIDS in SHIV(89.6P)-infected rhesus monkeys. 
  • Variability in repeated consecutive measurements of plasma human immunodeficiency virus RNA in persons receiving stable nucleoside reverse transcriptase inhibitor therapy or no treatment. 
  • WHO's new HIV guidelines: opportunities and challenges. 
  • Zidovudine administered to women infected with human immunodeficiency virus type 1 and to their neonates reduces pediatric infection independent of an effect on levels of maternal virus. 
  • Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. 
• 

  Keywords of People

  • Barker, Piers Christopher Andrew, Professor of Pediatrics, Pediatrics, Cardiology
  • Ferrari, Guido, Professor in Surgery, Molecular Genetics and Microbiology